AKYA Akoya Biosciences 添加自选 2.450 -0.090-3.54% 收盘价 12/18 16:00 (美东) 2.330 -0.120-4.90% 盘后20:01 (美东) 1.21亿总市值-2.11市盈率TTM 2.630最高价2.350最低价20.48万股成交量2.570今开2.540昨收51.36万成交额1.27%换手率亏损市盈率(静)4956.34万总股本6.31052周最高8.91市净率3967.42万流通值...
最近访问:Akoya Biosciences Inc --- 全球指数美股行情美股吧国际期货 - -- 今开: - 最高价: - 成交量: - 外盘: - 昨收: - 最低价: - 成交额: - 内盘: - 总股本: - 振幅: - 换手率: - 每股收益TTM: - 总市值: - 市净率MRQ: - ...
手机东方财富网是东方财富网的手机门户网站,为亿万用户打造一个手机联通世界的超级平台,提供7*24小时全面及时的财经中文资讯,内容覆盖国内外突发事件、股市资讯、全球新闻、产业资讯、实用信息等。手机东方财富网触屏版 - eastmoney.com
AKYA Akoya Biosciences 添加自选 1.630 -0.020-1.21% 收盘价 02/28 16:00 (美东) 8080.36万总市值-1.41市盈率TTM 1.690最高价1.590最低价18.60万股成交量1.650今开1.650昨收30.40万成交额1.22%换手率亏损市盈率(静)4957.27万总股本5.26052周最高5.93市净率2477.06万流通值1.59052周最低--股息TTM1519.67万流通股28.9...
Featured Products Opal 480 Reagent Pack SKU:FP1500001KT Formerly Opal Polaris 480 Reagent Pack Opal™ is a practical workflow for simultaneous detection of up to 6 tissue biomarkers plus nuclear counterstain, within a single image. The method is similar to standard immunohistochemistry and is acces...
公司名称: Akoya Biosciences, Inc. 所属行业: 健康科技 / 生物技术 交易所: 纳斯达克交易所 股票分析 最近更新于 2025-02-21 2 超过18%的股票 行业排名 216/288 市场排名 4047/4921 机构预测 当前价 $2.050 目标均价 $3.60 最高目标价 $5.00 最低目标价 $3.00 有8家机构对目标价进行预测 营收...
As The Spatial Biology Company®, Akoya Biosciences’ mission is to bring context to the world of biology and human health through the power of spatial phenotyping. The company offers comprehensive single-cell imaging solutions that allow researchers to phenotype cells with spatial context and visual...
The PhenoCycler System (formerly CODEX) overcomes challenges of traditional multiplexed immunofluorescence, by targeting subsets of the antibody panel through iterative imaging cycles, thus revealing 100+ biomarkers in a single tissue section.
Akoya Biosciences’ Technology Enables Queensland Spatial Biology Centre to Revolutionize... Akoya Biosciences Announces that Garry Nolan, Ph.D., James Allison, Ph.D., and Padmanee Sharma, M.D... Akoya Biosciences and Thermo Fisher Scientific Announce a License and Distribution Agreement to Deliver...
Financials SEC Filings Quarterly Results Governance Documents & Charters Board of Directors Management Team Committee Composition IR Resources Investor FAQs Investor Contact Investor Educational Resources Year February 5, 2025 Akoya Biosciences Unveils Strategic Product Roadmap, Powered by the New IO60 and ...